Paige gets CE mark for prostate cancer detection technology

The software is designed to make it easier for pathologists to analyze biopsies for signs of cancer.

By Nick Paul Taylor • Nov. 13, 2019

FDA grants breakthrough status to AI-based gastric cancer diagnostic

The technology uses artificial intelligence to analyze endoscopy images for signs of gastric cancer.

By Nick Paul Taylor • Nov. 12, 2019

Explore the Trendline➔

New medical devices are reshaping the medtech industry

From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

By MedTech Dive staff

Exact Sciences closes Genomic Health deal, wins breakthrough tag for liver cancer blood test

The Cologuard maker said it intends to roll out the test for hepatocellular carcinoma in the second half of 2020.

By Maria Rachal • Nov. 8, 2019

Triple-digit liquid biopsy growth powers Guardant to beat-and-raise quarter

Guardant Health raised its full-year revenue guidance by around 10% after blasting past expectations.

By Nick Paul Taylor • Nov. 8, 2019

Hologic beats sales outlook on diagnostics, breast health

The women's health-focused company said it's planning to fuel further growth with more tuck-in acquisitions. But analysts gave a muted response to the results and shares were down 5% Thursday morning. 

By Nick Paul Taylor • Nov. 7, 2019

FDA authorizes 1st NGS test for HIV drug resistance mutation

By detecting 342 HIV drug resistance mutations in blood samples, the next-generation sequencing test gives physicians a different way to assess resistance and tailor treatments to patients, the agency said.

By Nick Paul Taylor • Nov. 6, 2019

Myriad shares plunge 40% after missing targets, slashing outlook

Investors punished the genetic test maker after it reported double-digit drops in sales of its key cancer and depression products.

By Nick Paul Taylor • Nov. 5, 2019

Sharp drop in Chinese sales drags Qiagen down in Q3

Sales in China fell 24% in the quarter, which Qiagen attributed to a slowdown in distributor orders and the end of its next generation sequencing joint venture.

By Nick Paul Taylor • Oct. 31, 2019

Exact Sciences Q3 revenue jumps 85% but Cologuard orders disappoint

Shares in the non-invasive colon cancer test manufacturer fell approximately 6% Wednesday. Exact plans to focus on increasing payer coverage of Cologuard and communicating its label expansion to doctors.

By David Lim • Oct. 30, 2019

CMS proposes lifting restrictions on NGS cancer testing

The agency revised its proposed national coverage determination after receiving more than 80 comments, with potential plans to extend coverage of next generation sequencing tests to earlier-stage and hereditary cancers.

By Nick Paul Taylor • Oct. 30, 2019

UK regulator mulls blocking Illumina's $1.2B PacBio takeover

The watchdog said the union "would result in a significant reduction of competition," leading some analysts to predict the deal won't go through.

By Nick Paul Taylor • Oct. 25, 2019

Rivals LabCorp and Quest post improved outlooks despite PAMA woes

Quest's volume gains exceeded those of rival LabCorp, but came at the expense of its revenues per requisition, which fell 1.2% in the third quarter.

By Nick Paul Taylor • Oct. 24, 2019

Device to ID obstructions in post-PCI patients wins breakthrough status

Swiss startup CorFlow Therapeutics created the device to both assess and treat microvascular obstruction in patients after percutaneous coronary intervention.

By Nick Paul Taylor • Oct. 24, 2019

J&J reports rising success rate in robotic surgery clinical trial

The study is assessing diagnostic abilities of the Monarch robotic surgery platform, which Johnson & Johnson gained in the $3.4 billion acquisition of Auris Health.

By Nick Paul Taylor • Oct. 24, 2019

Medtronic rolls out AI-assisted colonoscopy system in Europe

The medtech giant expects to introduce the system in the U.S. market in the second half of 2020, a company spokesperson told MedTech Dive.

By Susan Kelly • Oct. 21, 2019

Abbott 'working through a handful of items' with FDA on FreeStyle Libre 2

Third-quarter revenue for the medtech came in at $8.08 billion, slightly below Wall Street expectations, but executives praised the growth of key products FreeStyle Libre, MitraClip and Alinity on its earnings call.

By David Lim • Oct. 16, 2019

Ancestry takes on 23andMe, rolls out genetic health test services

The company will be working with Quest Diagnostics and Illumina to sell the laboratory developed tests. It does not currently have a relationship with LabCorp, according to an executive.

By David Lim • Oct. 15, 2019

Medical software makers get new guidance on MDR, IVDR

The European Commission's Medical Device Coordination Group aims to clarify which software will be subject to the new regulations, and how those products should be classified and placed on the market.

By Dana Elfin • Oct. 14, 2019

FDA clears first rapid Ebola virus diagnostic

Risk of flare up remains, but the United Nations called the outbreak responsible for killing 2,100 people over 14 months in the Democratic Republic of the Congo "significantly contained."

By Nick Paul Taylor • Oct. 11, 2019

CDS software, labels for staplers and breast implants among FDA 2020 guidance priorities

The annual publication comes days after the White House issued an executive order aimed at limiting agency use of the documents.

By David Lim • Oct. 11, 2019

Experimental cancer IVD trial guidance finalized

AdvaMed won many many of the changes it sought during the comment period, including ones related to communication with the FDA.

By Nick Paul Taylor • Oct. 10, 2019

Fresenius to pay $5.2M to settle Medicare overbilling allegations

DOJ alleged the company overbilled Medicare for more than seven years by ordering hepatitis B tests for patients it knew to be immune to the virus.

By Nick Paul Taylor • Oct. 10, 2019

Qiagen taps new CEO, restructures in 'clearly a bad day'

The company is also suspending next-generation sequencing-related instrument development as it pivots into a 15-year partnership with Illumina to develop in vitro diagnostic kits.

By David Lim • Oct. 8, 2019

Lantheus strikes deal to buy Progenics, sparking investor backlash

Velan Capital, a big shareholder in Progenics, accused management of selling at a "massive discount" and preventing investors from being heard.

By Nick Paul Taylor • Oct. 3, 2019

Former Covance CEO out as LabCorp diagnostics chief a month after appointment

Newly minted diagnostics CEO John Ratliff is departing the company. LabCorp reshuffled two supply chain and managed care execs to fill the void.

By David Lim • Updated Nov. 7, 2019